More research is necessary to determine whether flutamide is effective in the treatment of OCD. References
Further reading
Sogani PC, Whitmore WF (1988). "Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma". Cancer Treat. Res. Cancer Treatment and Research. 39: 131–45. doi:10.1007/978-1-4613-1731-9_9. ISBN 978-1-4612-8974-6. PMID 2908604. Brogden RN, Clissold SP (1989). "Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer". Drugs. 38 (2): 185–203. doi:10.2165/00003495-198938020-00003. PMID 2670515. Neri R (1989). "Pharmacology and pharmacokinetics of flutamide". Urology. 34 (4 Suppl): 19–21, discussion 46–56. doi:10.1016/0090-4295(89)90230-6. PMID 2477934. Newling DW (1989). "The use of flutamide as monotherapy in the treatment of advanced prostate cancer". Prog. Clin. Biol. Res. 303: 117–21. PMID 2674980. Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J (1989). "Combination therapy with castration and flutamide: todays treatment of choice for prostate cancer". J. Steroid Biochem. 33 (4B): 817–21. doi:10.1016/0022-4731(89)90499-8. PMID 2689788. Goldspiel BR, Kohler DR (1990). "Flutamide: an antiandrogen for advanced prostate cancer". DICP. 24 (6): 616–23. doi:10.1177/106002809002400612. PMID 2193461. S2CID 26125621. Brogden RN, Chrisp P (1991). "Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer". Drugs Aging. 1 (2): 104–15. doi:10.2165/00002512-199101020-00003. PMID 1794008. Labrie F (1993). "Mechanism of action and pure antiandrogenic properties of flutamide". Cancer. 72 (12 Suppl): 3816–27. doi:10.1002/1097-0142(19931215)72:12+<3816::aid-cncr2820721711>3.0.co;2-3. PMID 8252497. S2CID 2195250. Iversen P, Melezinek I, Schmidt A (2001).
Dilation and/or rupture (aneurysm) of ascending aorta
Cardiovascular autonomic dysfunction such as postural orthostatic tachycardia syndrome
Raynauds phenomenon
Varicose veins
Heart murmur
Heart conduction abnormalities

Other manifestations
Hiatal hernia
Gastroesophageal reflux
Poor gastrointestinal motility
Dysautonomia
Gorlins sign (touch tongue to nose)
Anal prolapse
Flat feet
Tracheobronchomalacia / tracheal collapse
Collapsed lung (spontaneous pneumothorax)
Nerve disorders (carpal tunnel syndrome, acroparesthesia, neuropathy, including small fiber neuropathy)
Insensitivity to local anesthetics
Arnold–Chiari malformation
Platelet aggregation failure (platelets do not clump together properly)
Mast cell disorders (including mast cell activation syndrome and mastocytosis)
Pregnancy complications: increased pain, mild to moderate peripartum bleeding, cervical insufficiency, uterine tearing, or premature rupture of membranes
Hearing loss may occur in some types
Eye: Nearsightedness, retinal tearing and retinal detachment, keratoconus, blue sclera, dry eye, Sjogrens syndrome, lens subluxation, angioid streaks, epicanthal folds, strabismus, corneal scarring, brittle cornea syndrome, cataracts, carotid-cavernous sinus fistulas, macular degeneration
Craniocervical instability: caused by trauma(s) to the head and neck areas such as concussion and whiplash. Ligaments in neck are unable to heal properly, so the neck structure does not have the ability to support the skull, which can then sink into the brain stem, blocking the flow of cerebrospinal fluid, leading to issues related to the autonomic nervous system failing to work properly. Osteoporosis and osteopenia are associated with EDS and symptomatic joint hypermobility
There is some evidence that EDS may be associated with greater than expected frequencies of neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and other learning, communication and motor issues, including autism spectrum conditions and Tourette syndrome. Because it is often undiagnosed or misdiagnosed in childhood, some instances of EDS have been mischaracterized as child abuse.